Evaluation of Food Effect on the Pharmacokinetics of Velufenacin, a New Muscarinic Receptor Antagonist, in Healthy Subjects

Abstract

AbstractVelufenacin (DA‐8010) is a new muscarinic receptor antagonist under development for the treatment of overactive bladder. This study aimed to evaluate the effect of food on the pharmacokinetics (PK) and safety of velufenacin in healthy subjects. A randomized, open‐label, single‐dose, 4‐sequence, 4‐treatment, 4‐period crossover study was conducted. Subjects received a single oral dose of velufenacin 2.5 or 5 mg in a fasted or fed (high‐fat meal) state in each period with a 7‐day washout. PK parameters including maximum plasma concentration (Cmax) and area under the concentration‐time curve from time 0 to the last measurable point were compared between the fed and fasted states. Twenty‐seven subjects completed the study. The mean area under the concentration‐time curve from time 0 to the last measurable point of the velufenacin 2.5 and 5 mg doses under the fed condition showed a 1.5‐ and 1.3‐fold increase, respectively, compared to the fasted condition. The corresponding values for Cmax were a 2.3‐ and 2.0‐fold increase, respectively. The time to reach Cmax was comparable regardless of the dose or food intake, showing median values of 4.5‐5.0 hours. These results suggest a modest increase of velufenacin absorption by food intake. Velufenacin was generally safe and well tolerated at the 2.5 and 5 mg doses regardless of food.